Von Willebrand Disease (VWD) Market Research Report present a detailed analysis of the market listing Von Willebrand Disease (VWD) Epidemiology, Drug therapies and pipeline for study period from 2016-2018.

Von Willebrand Disease (VWD) Market Size & Share | Von Willebrand Disease (VWD) Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight's "Von Willebrand Disease Market Insight, Epidemiology and Market Forecast-2028" report deliver an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, France, Italy, Spain , and the United Kingdom), and Japan. Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 0-18 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 19-44 years reported higher diagnosed prevalence than that of people belonging to other age groups. <h2>Geography Covered</h2> • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan <h2>Study Period: 2017-2028</h2> <h2>Von Willebrand Disease (VWD)—Disease Understanding and Treatment Algorithm</h2>Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process.Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. Inherited forms are further subdivided into Type 1, 2, and 3 along with a pseudo-VWD. Platelet type disorder which in turn describes their pathophysiology. Type 1 is easily distinguished from type 3 by its milder deficiency and is characterized by a decreased quantity of vWF whereas Type 2 is distinguished on the basis of functional or qualitative deficiencies. <h2>Von Willebrand Disease (VWD) Epidemiology</h2>The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain , and the United Kingdom) and Japan from 2017 to 2028.According to DelveInsight, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 2017-2028. <h2>Von Willebrand disease (VWD) Drug Chapters</h2>The current therapeutic landscape of Von Willebrand disease can be divided into three major categories based on the class of drugs administered, they are; Non-replacement Therapy using desmopressin (DDAVP) to increase the plasma concentration of vWF, Replacement Therapy using plasma-derived coagulation factor concentrates (Humate-P, Alphanate, Immunate, and Wilate), and Adjunct Therapy using primarily anti-fibrinolytics, such as Tranexamic Acid (Cyclokapron).A new category of recombinant coagulation factor concentrates -Vonvendi (Shire) has recently entered the replacement therapy segment. The approved (and their generic versions) as well as off-label products that are being used for the treatment of von Willebrand Disease, and contributing toward the market revenue, belong to either of these above-mentioned therapeutic classes.Non-replacement therapy includes Desmopressin, which has been used as the first-line of treatment mostly for patients suffering from the Type 1 variants and a few Type-2 cases. Stimate (CSL Behring GmbH), DDAVP (Sanofi-Aventis), and Octostim (CSL Behring GmbH) with desmopressin acetate being the active ingredient are some of the drugs which belong to this category. The gradual emergence of virally-inactivated FVIII concentrates containing VWF for the treatment of hemophilia A proved a more optimal replacement therapeutic option for patients with VWD. Currently, they form the second-line of treatment especially during severe bleeding episodes of Type 1 variant as well as Type 2 and Type 3. In the United States, VWD is typically treated with either Humate-P (CSL Behring) or Wilate (Octapharma) or Alphanate (Grifols), which is identical to Fanhdi, made in Spain. Adjunct or supportive therapies mainly include antifibrinolytic agents, such as tranexamic acid (Cyclokapron) and amiococaproic acid (Amicar) which work by inhibiting the interaction of plasminogen with fibrin, thus preventing the degradation of the fibrin clot. <h2>Von Willebrand disease (VWD) Market Outlook</h2>According to DelveInsight, the market of Von Willebrand disease (VWD) in 7MM was found to be approximately USD 397.20 million in 2017.&nbsp;Among the EU5 countries, the United Kingdom had the highest market size with USD 61.62 million in 2017, while Spain had the lowest market size of Von Willebrand Disease with USD 6.37 million in 2017. <h2>Von Willebrand disease (VWD) Drugs Uptake</h2>Overall, the increasing diagnosed prevalence of the disease along with the promising expanded recombinant therapies will fuel the market during the forecasted period of 2019-2028 with some of the major players in the VWD treatment market being Shire Plc. (earlier Baxalta), CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.The recent launch of Shire's Vonvendi/Veyvondi in the US and the expected launch in EU in 2019 have the potential to create a significant positive shift in the von Willebrand Disease market size. Expected launch of Wilfactin (LFB Biomedicaments) in 2021 (will file in the US) will also create a positive impact on the VWD market in US. <h2>Von Willebrand disease (VWD) Report Insights</h2> • Patient Population by total diagnosed cases • Gender-specific diagnosed population • Type-specific diagnosed population • Age-specific diagnosed population • Therapeutic Approaches • Pipeline Analysis • Market Size and Trends • Market Opportunities • Impact of upcoming Therapies <h2>Von Willebrand disease (VWD) Report Key Strengths</h2> • 10-Year Forecast • 7MM Coverage • Epidemiology Segmentation • Drugs Uptake • Highly Analyzed Market • Key Cross Competition <h2>Von Willebrand disease (VWD) Report Assessment</h2> • Current Treatment Practices • Unmet Needs • Detailed Pipeline Product Profiles • Market Attractiveness • Market Drivers and Barriers <h2>Key Benefits</h2> • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Von Willebrand disease (VWD) market. • Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand disease (VWD) market. • To understand the future market competition in the Von Willebrand disease (VWD) market.

1. Key Insights 2. Von Willebrand Disease (VWD): Market Overview at a Glance 2.1. Total Market Share (%) Distribution of VWD in 2017 2.2. Total Market Share (%) Distribution of VWD in 2028 3. Disease Background and Overview: Von Willebrand Disease (VWD) 3.1. Introduction 3.2. Symptoms of Von Willebrand disease 3.3. Classification of Von Willebrand disease 3.4. Causes of Von Willebrand disease (VWD) 3.5. Clinical Manifestations of Von Willebrand disease (VWD) 3.6. Genetic Basis of Von Willebrand disease 3.7. Pathophysiology of Von Willebrand disease (VWD) 3.8. Diagnosis of Von Willebrand disease 3.9. Diagnostic Guidelines of Von Willebrand disease (VWD) 3.9.1. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health 3.9.2. The diagnosis of von Willebrand disease: a guideline from the UK Hemophilia Centre Doctor's Organization 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease 5. Country Wise-Epidemiology of von Willebrand Disease 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United States 5.1.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States 5.1.4. Type Specific Diagnosed Prevalent Population of Von Willebrand Disease in the United States 5.1.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United States 5.2. EU5 Countries 5.2.1. Germany 5.2.1.1. Assumptions and Rationale 5.2.1.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Germany 5.2.1.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany 5.2.1.4. Type-Specific Diagnosed Prevalence of von Willebrand Disease in Germany 5.2.1.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Germany 5.2.2. France 5.2.2.1. Assumptions and Rationale 5.2.2.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in France 5.2.2.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in France 5.2.2.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in France 5.2.2.5. Age-Specific Diagnosed Prevalent Population of Von Willebrand Disease in France 5.2.3. Italy 5.2.3.1. Assumptions and Rationale 5.2.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Italy 5.2.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Italy 5.2.3.4. Type Specific Diagnosed Prevalence of von Willebrand Disease in Italy 5.2.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Italy 5.2.4. Spain 5.2.4.1. Assumptions and Rationale 5.2.4.2. Total Diagnosed Prevalent Population of Von Willebrand Disease in Spain 5.2.4.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain 5.2.4.4. Type Specific Diagnosed Prevalence of Von Willebrand Disease in Spain 5.2.4.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Spain 5.2.5. United Kingdom 5.2.5.1. Assumptions and Rationale 5.2.5.2. Total Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom 5.2.5.3. Gender-Specific Diagnosed Prevalent Population of von Willebrand Disease in the UK 5.2.5.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in the United Kingdom 5.2.5.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in the United Kingdom 5.3. Japan 5.3.1. Assumptions and rationale 5.3.2. Total Diagnosed Prevalent Population of von Willebrand Disease in Japan 5.3.3. Gender-Specific Diagnosed Prevalent Population of Von Willebrand Disease in Japan 5.3.4. Type-Specific Diagnosed Prevalence of Von Willebrand Disease in Japan 5.3.5. Age-Specific Diagnosed Prevalent Population of von Willebrand Disease in Japan 6. Treatment Algorithm, Current Treatment, and Medical Practices 6.1. 2012 Clinical Practice Guideline on the Evaluation and Management of von Willebrand Disease (VWD) 6.2. The Diagnosis, Evaluation, and Management of von Willebrand Disease from the National Heart Lung and Blood Institute, National Institutes of Health 6.3. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology 7. Unmet Needs 8. Marketed Drugs 8.1. Key Cross Competition 8.2. Vonvendi: Shire 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages and Disadvantages 8.2.5. Clinical Development 8.2.6. Clinical Trials Information 8.2.7. Safety and Efficacy 8.2.8. Product Profile 8.3. Voncento: CSL- Behring 8.3.1. Drug Description 8.3.2. Mechanism of Action 8.3.3. Regulatory Milestones 8.3.4. Advantages and Disadvantages 8.3.5. Clinical Development 8.3.6. Clinical Trials Information 8.3.7. Safety and Efficacy 8.3.8. Product Profile 8.4. Humate-P/Haemate P: CSL Behring 8.4.1. Drug Description 8.4.2. Mechanism of Action 8.4.3. Regulatory Milestones 8.4.4. Advantages and Disadvantages 8.4.5. Safety and Efficacy 8.4.6. Product Profile 8.5. Wilate: Octapharma 8.5.1. Drug Description 8.5.2. Mechanism of Action 8.5.3. Regulatory Milestones 8.5.4. Advantages and Disadvantages 8.5.5. Clinical Development 8.5.6. Clinical Trials Information 8.5.7. Safety and Efficacy 8.5.8. Product Profile 8.6. Wilfactin/Wilfact: LFB Biomedicaments 8.6.1. Drug Description 8.6.2. Mechanism of Action 8.6.3. Regulatory Milestones 8.6.4. Advantages and Disadvantages 8.6.5. Product Profile 8.7. Desmopressin: Ferring Pharmaceuticals 8.7.1. Drug Description 8.7.2. Mechanism of Action 8.7.3. Regulatory Milestones 8.7.4. Advantages and Disadvantages 8.7.5. Product Profile 8.8. Alphanate: Grifols Biological Inc. 8.8.1. Drug Description 8.8.2. Mechanism of Action 8.8.3. Regulatory Milestones 8.8.4. Advantages and Disadvantages 8.8.5. Safety and Efficacy 8.8.6. Product Profile 8.9. Fanhdi: Grifols Biological Inc. 8.9.1. Drug Description 8.9.2. Mechanism of Action 8.9.3. Regulatory Milestones 8.9.4. Advantages and Disadvantages 8.9.5. Safety and Efficacy 8.9.6. Product Profile 9. Von Willebrand Disease: 7 Major Market Analysis 9.1. Key Findings 9.2. Market Size of Von Willebrand Disease in 7MM 9.3. Market Size by therapies of Von Willebrand Disease in 7MM 10. The United States Market Outlook 10.1. United States Market Size 10.1.1. Total Market size of Von Willebrand Disease 10.1.2. Market Size by Therapies 11. EU-5 Countries: Market Outlook 11.1. Germany 11.1.1. Total Market size of von Willebrand Disease in Germany 11.1.2. Market Size by Therapies 11.2. France 11.2.1. Total Market size of Von Willebrand Disease 11.2.2. Market Size by Therapies 11.3. Italy 11.3.1. Total Market size of von Willebrand Disease 11.3.2. Market Size by Therapies 11.4. Spain 11.4.1. Total Market size of von Willebrand Disease 11.4.2. Market Size by Therapies 11.5. United Kingdom 11.5.1. Total Market size of Von Willebrand Disease 11.5.2. Market Size by Therapies 11.6. Japan: Market Outlook 11.6.1. Total Market size of von Willebrand Disease 11.6.2. Market Size by Therapies 12. Market Drivers 13. Market Barriers 14. Appendix 14.1. Report Methodology 15. DelveInsight Capabilities 16. Disclaimer 17. About DelveInsight

Von Willebrand Disease (VWD) - Market Insight, Epidemiology and Market Forecast - 2028

DelveInsight's 'Von Willebrand Disease (VWD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 

Customize Reports As Per Your Needs